Chemistry: molecular biology and microbiology – Animal cell – per se ; composition thereof; process of... – Primate cell – per se
Patent
1995-06-02
1998-10-20
Chambers, Jasemine C.
Chemistry: molecular biology and microbiology
Animal cell, per se ; composition thereof; process of...
Primate cell, per se
435325, 435366, 4351723, 514 44, 424 9321, 530350, 536 231, C12N 508
Patent
active
058245499
ABSTRACT:
Medicaments and methods of using the same are disclosed for treating or preventing diseases resulting from undesirable cell adhesion of IL-1 receptor positive cells to biological materials, particular to endothelial cells, or autoimmune related diseases, preferably graft versus host disease, or IL-1 dependent cancers.
REFERENCES:
patent: 5011778 (1991-04-01), Newman et al.
patent: 5075222 (1991-12-01), Hannum et al.
patent: 5180812 (1993-01-01), Dower et al.
patent: 5359032 (1994-10-01), Dayer et al.
patent: 5455330 (1995-10-01), Haskill et al.
Levy, J. A. Pathogenesis of Human Immunodeficiency Virus Infection. Microbiological Reviews, vol. 57, No. 1, pp. 183-289, Mar. 1993.
Johnston et al. Present status and future prospects for HIV therapies. Science, vol. 260, pp. 1286-1293, May 28, 1993.
Orkin et al. Report and recommendations of the panel to assess the NIH investment in research on gene therapy, Dec. 7, 1995.
Carter, et al., "Purification, cloning, expression and biological characterization of an interleukin-1 receptor antagonist protein," Nature 344:633-638 (Apr. 12, 1990).
Cominelli, et al., "Interleukin 1 (IL-1) Gene Expression, Synthesis, and Effect of Specific IL-1 Receptor Blockade in Rabbit Immune Complex Colitis," J. Clin. Invest., 86:972-980 (Sep. 1990).
Dinarello, et al., "Multiple Biological Activities of Human Recombinant Interleukin 1," J. Clin. Invest., 77:1734-1739 (Jun. 1986).
Eisenberg, et al., "Primary structure and functional expression from complementary DNA of a human interleukin-1 receptor antagonist," Nature, 343:341-346, (Jan. 25, 1990).
Fanslow, et al., "Regulation of Alloreactivity in Vivo by a Soluble Form of the Interleukin-1 Receptor," Science, 248:739-742, (May 1990).
Gosset, et al., "Production of an Interleukin-1 Inhibitor Factor by Human Alveolar Macrophages from Normals and Allergic Asthmatic Patients," Am. Rev. Respir. Dis., 138:40-46 (1988).
Gershenwald, et al., "Interleukin 1 receptor blockade attenuates the host inflammatory response," Proc. Natl. Acad. Sci. USA, 87:4966-4970 (Jul. 1990).
Hannum, et al., "Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor," Nature, 343:336-339 (Jan. 25, 1990).
Maliszewski, et al., "Cytokine Receptors and B Cell Functions-1. Recombinant Soluble Receptors Specifically Inhibit IL-1- and IL-4-Induced B Cell Activities in Vitro," The Journal of Immunology, 144:3028-3033, No.8 (Apr. 15, 1990).
Oppenheim, et al., "There is More Than One Interleukin 1," Immunology Today, Reviews, 7:45-56 No. 2 (1986).
Palaszynski, "Synthetic C-Terminal Peptide of IL-1 functions as a Binding Domain As Well As An Antagonist For The IL-1 Receptor," Biochemical and Biophysical Research Communications, 147:204-211, No. 1 (Aug. 31, 1987).
Seckinger, et al., "A Urine Inhibitor of Interleukin 1 Activity Affects Both Interleukin 1.alpha. and 1.beta. But Not Tumor Necrosis Factor .alpha.," The Journal of Immunology, 139:1541-1545, No. 5 (Sep. 1, 1987).
Simpson, et al., "Reduction of Experimental Canine Myocardial Reperfusion Injury by a Monoclonal Antibody (Anti-Mol, Anti-CD11b) That Inhibits Leukocyte Adhesion," J. Clin. Invest., 81:624-629 (Feb. 1988).
Dorland's Illustrated Medical Dictionary, 24th Ed., W.B. Saunders Company, Philadelphia, PA., p. 760, defining "ischemia," (1965).
Vedder, et al., "A Monoclonal Antibody to he Adherence-promoting Leukocyte Glycoprotein, CD18, Reduces Organ Injury and Improves Survival from Hemorrhagic Shock and Resuscitation in Rabbits," J. Clin. Invest., 81:939-944 (1988).
Cotran, et al., "Induction and Detection of a Human Endothelial Activation Antigen In Vivo," Brief Definitive Report, J. Exp. Med. 164: 661-666, (Aug. 1986).
Buchan, et al., "Interleukin-1 and tumor necrosis factor mRNA expression in rheumatoid arthritis: prolonged production of IL-1.alpha.," Clin. Exp. Immunol. 73:449-455 (Mar. 1988).
Haskill John Stephen
Ralph Peter
Blackburn Robert P.
Chambers Jasemine C.
Chiron Corporation
Clark Deborah J. R.
Pochopien Donald J.
LandOfFree
Transformed human T cell does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Transformed human T cell, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Transformed human T cell will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-243570